Publications

Academic Publications 

1. Kaur, Harpreet, et al. "Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder." Psychedelic Medicine (2023)

- https://www.liebertpub.com/doi/10.1089/psymed.2023.0023

2. Karabulut, Sedat, Harpreet Kaur, and James W. Gauld. "Applications and Potential of In Silico Approaches for Psychedelic Chemistry." Molecules 28.16 (2023): 5966.

- https://www.mdpi.com/1420-3049...

3. Karabulut, Sedat, Harpreet Kaur, and James W. Gauld. ”Uncovering Structure–Activity Relationships of Phenethylamines: Paving the Way for Innovative Mental Health Treatments” ACS Chem. Neurosci. February 2024

- https://pubs.acs.org/doi/abs/10.1021/acschemneuro.3c00677

Patents

1. US2023/0201159 A1, Assignee: PharmAla Biotech, Inventors: Kadysh N, Howell L, Kaur H

- Full text here: https://patentimages.storage.g...

2. WO2022232949A1

- Full text here: https://patents.google.com/pat...

3. WO/2024/020696, Assignee: PharmAla Biotech, Inventors: Harpreet Kaur, Tao Xin

- Full text here: https://patents.google.com/patent/WO2024020696A1/en?oq=WO2024020696...

4. US2024/12042478 B2 Assignee: PharmAla Biotech, Inventors: Harpreet Kaur, Tao Xin

- Full text here: https://pharmala.ca/assets-ima...

Conferences

Invited Talks:

1. Harpreet Kaur, Psychedelics as Therapeutics, Bass Coast 2022

2. Harpreet Kaur, Psychedelics: Safety Considerations, Bass Coast 2023

3. Harpreet Kaur, Trials to Triumph – Realizing your pharmacology potential., 2024

Invited Panel Discussions:

1. Philippe Lucas, Danny Motkya, Spencer Hawkswell, Harpreet Kaur “The Future of Psychedelic Use and Research in Canada”, Grow Up Victoria, Canada, June 20-22, 2022

2. Tom McDonald, Clare Knight, James Lanthier, Harpreet Kaur: “Overcoming the Complexities of Psychedelic Trials”, 3rd Annual Psychedelic Therapeutics and Drug Development Conference, San Francisco, May 23-24, 2023

Poster Presentations:

1. Holloway KH, Shaw HE; Kaur H, and Fantegrossi WE, Cardiovascular effects of methamphetamine, 3,4-methylenedioxymethamphetamine, and other entactogens in C57BL/6 and BTBR T+ Itpr3tf/J mice.(2023) 15th Annual Behavior, Biology and Chemistry: Translational Research in Substance Use Disorders

View poster here

2. Bierbaum CG, Shaw HE; Kaur H and Fantegrossi WE, Effects of S-methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers on place conditioning in C57BL/6 and BTBR T+ Itpr3tf/J mice. (2023) 15th Annual Behavior, Biology and Chemistry: Translational Research in Substance Use Disorders

View poster here

3. Fagot SA, Shaw HE; Kaur H and Fantegrossi WE. Thermoregulatory and locomotor effects of 3,4-methylenedioxy-methamphetamine (MDMA), its enantiomers, and a non-racemic mixture.(2023) 15th Annual Behavior, Biology and Chemistry: Translational Research in Substance Use Disorders

View poster here

4. Clark, Mia R; Shaw, Hannah E; Kaur H & Fantegrossi, William E. In vivo characterization of MBDB and its enantiomers in C57BL/6 and autism-like BTBR T+Itpr3tf/J mice. (2024) 16th Annual Behavior, Biology and Chemistry: Translational Research in Substance Use Disorders 

View poster here